Company Overview

Titan Biotech Limited (CIN: L74999RJ1992PLC013387) is a leading manufacturer and exporter of biological products used in pharmaceuticals, nutraceuticals, food & beverages, biotechnology, cosmetics, and veterinary applications. The company operates four manufacturing facilities in Rajasthan and filed its 34th Annual General Meeting notice and Annual Report for FY 2025-26.

Financial Performance Highlights

FY 2025-26 vs FY 2024-25:

  • Consolidated revenue from operations: ₹206.19 crore (vs ₹156.45 crore), growth of 31.8%
  • Consolidated net profit: ₹298.85 crore (vs ₹215.32 crore), growth of 38.8%
  • Standalone revenue: ₹20,619.03 lakhs with profit after tax of ₹2,744.72 lakhs
  • Basic EPS: ₹7.23 (FY25: ₹5.21); Standalone EPS: ₹6.64 (FY25: ₹4.42)
  • Export revenue surged 49% to ₹80.33 crore, now representing 39% of total revenue
  • Effective tax rate: 28.1% with current tax of ₹9.89 crore

AGM Details & Corporate Actions

Meeting Scheduled: September 29, 2026 at 3:00 PM IST via video conferencing

Record Date: September 22, 2026 for dividend eligibility

E-voting Period: September 26-28, 2026

Key Agenda Items:

  • Adoption of audited financial statements for FY ended March 31, 2026
  • Declaration of final dividend of ₹0.50 per equity share
  • Re-appointment of directors including Ms. Supriya Singla and Mr. Shivom Singla
  • Increase in authorized share capital from ₹10 crore to ₹10.40 crore
  • Issue of bonus shares in 1:4 ratio (one new bonus share for every four existing shares)
  • Re-appointment of Mr. Rohit Jain as Independent Director for second five-year term
  • Authorization for loans/guarantees to subsidiaries up to ₹12 crores
  • Ratification of cost auditor remuneration and mortgage creation authorization

Capital Structure & Shareholding

Equity Capital:

  • Authorized capital: 500,00,000 equity shares of ₹2 each (₹100.00 crore)
  • Paid-up capital: ₹8,26,37,000 divided into 4,13,18,500 equity shares of ₹2 each
  • Stock subdivision implemented from ₹10 to ₹2 per share effective February 20, 2026

Shareholding Pattern (March 31, 2026):

  • Promoters & Promoter Group: 55.78% (2,30,47,520 shares)
  • Public: 44.22% (1,82,70,980 shares)
  • 100% shares dematerialized (CDSL: 69.66%, NSDL: 30.34%)

Financial Position & Borrowings

Assets & Liabilities (March 31, 2026):

  • Total assets: ₹213.88 crore
  • Non-current assets: ₹128.64 crore (PPE: ₹51.34 crore, Investments: ₹60.36 crore)
  • Current assets: ₹85.24 crore (Inventories: ₹55.77 crore, Trade receivables: ₹22.83 crore)
  • Equity: ₹181.55 crore; Liabilities: ₹32.34 crore
  • Secured borrowings: ₹3.67 crore (working capital facilities from ICICI Bank and vehicle loans)

Security Arrangements:

  • Primary security: Hypothecation of stocks and book debts
  • Collateral security: Industrial plot in RIICO Kaharani, Rajasthan
  • Personal guarantees of four directors for secured loans

Corporate Governance & Compliance

Board Composition: 12 directors (5 executive, 2 non-executive non-independent, 5 non-executive independent, 1 woman director)

Board Meetings: 14 meetings held during FY 2025-26

Director Remuneration: Executive directors received ₹72 lakh to ₹141 lakh each

Auditor Appointments:

  • Statutory Auditors: M/s. A N S K & Associates (unmodified opinion)
  • Cost Auditors: M/s. Sanjay Kumar Garg & Associates
  • Internal Auditors: M/s. PGM & Associates
  • Secretarial Auditor: Mr. Amit Anand

Regulatory Compliance:

  • No material orders passed by regulators/courts impacting going concern
  • No fraud reported by auditors
  • All applicable secretarial standards complied with
  • Audit trail feature enabled in accounting software

Related Party Transactions & Investments

Associate Companies:

  • Peptech Biosciences Limited: 36.87% holding, sales of ₹3.89 crore, loan of ₹4.20 crore
  • Titan Media Limited: 48.44% holding
  • Share in profit of associates: ₹2.44 crore

CSR Activities:

  • CSR obligation: ₹56.00 lakh (2% of average net profit)
  • Actual spending: ₹56.50 lakh on education and animal welfare

Key Ratios & Performance Metrics

  • Current ratio: 3.28 times (FY25: 4.48 times)
  • Debt-equity ratio: 0.03 times (FY25: 0.02 times)
  • Return on equity: 17.84% (FY25: 15.28%)
  • Inventory turnover: 2.21 times (FY25: 1.85 times)
  • Trade receivables turnover: 9.90 times (FY25: 8.35 times)
  • Net profit margin: 13.31% (FY25: 11.68%)

All transactions with related parties were in ordinary course of business at arm's length basis, with no materially significant transactions requiring special disclosure.